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Anti-malarial landscape in Myanmar: 
results from a nationally representative survey 
among community health workers and the 
private sector outlets in 2015/2016
ACTwatch Group1*, , Si Thu Thein2, Hnin Su Su Khin2 and Aung Thi3
Abstract 
Background: In 2015/2016, an ACTwatch outlet survey was implemented to assess the anti-malarial and malaria 
testing landscape in Myanmar across four domains (Eastern, Central, Coastal, Western regions). Indicators provide an 
important benchmark to guide Myanmar’s new National Strategic Plan to eliminate malaria by 2030.
Methods: This was a cross-sectional survey, which employed stratified cluster-random sampling across four regions 
in Myanmar. A census of community health workers (CHWs) and private outlets with potential to distribute malaria 
testing and/or treatment was conducted. An audit was completed for all anti-malarials, malaria rapid diagnostic tests.
Results: A total of 28,664 outlets were approached and 4416 met the screening criteria. The anti-malarial market 
composition comprised CHWs (41.5%), general retailers (27.9%), itinerant drug vendors (11.8%), pharmacies (10.9%), 
and private for-profit facilities (7.9%). Availability of different anti-malarials and diagnostic testing among anti-malarial-
stocking CHWs was as follows: artemisinin-based combination therapy (ACT) (81.3%), chloroquine (67.0%), confirma-
tory malaria test (77.7%). Less than half of the anti-malarial-stocking private sector had first-line treatment in stock: 
ACT (41.7%) chloroquine (41.8%), and malaria diagnostic testing was rare (15.4%). Oral artemisinin monotherapy 
(AMT) was available in 27.7% of private sector outlets (Western, 54.1%; Central, 31.4%; Eastern; 25.0%, Coastal; 15.4%). 
The private-sector anti-malarial market share comprised ACT (44.0%), chloroquine (26.6%), and oral AMT (19.6%). 
Among CHW the market share was ACT (71.6%), chloroquine (22.3%); oral AMT (3.8%). More than half of CHWs could 
correctly state the national first-line treatment for uncomplicated falciparum and vivax malaria (59.2 and 56.9%, 
respectively) compared to the private sector (15.8 and 13.2%, respectively). Indicators on support and engagement 
were as follows for CHWs: reportedly received training on malaria diagnosis (60.7%) or national malaria treatment 
guidelines (59.6%), received a supervisory or regulatory visit within 12 months (39.1%), kept records on number of 
patients tested or treated for malaria (77.3%). These indicators were less than 20% across the private sector.
Conclusion: CHWs have a strong foundation for achieving malaria goals and their scale-up is merited, however gaps 
in malaria commodities and supplies must be addressed. Intensified private sector strategies are urgently needed and 
must be scaled up to improve access and coverage of first-line treatments and malaria diagnosis, and remove oral 
AMT from the market place. Future policies and interventions on malaria control and elimination in Myanmar should 
take these findings into consideration across all phases of implementation.
Keywords: Anti-malarial, Oral artemisinin monotherapy, Artemisinin combination therapy, Chloroquine,  
Malaria testing
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Background
Myanmar bears the highest malaria burden in the Greater 
Mekong Sub-region (GMS), accounting for around 70% 
of reported cases in the region. The incidence of reported 
malaria has dropped by about 49% since 2012 (from 8.09 
in 2012 to 4.16 in 2015 per 1000 population) [1]. Approx-
imately 16% of Myanmar’s population of 57 million live in 
areas of high transmission and another 44% live in areas 
of low transmission. Plasmodium falciparum makes up 
75% of the parasite species while Plasmodium vivax com-
prises the other 25% [2].
In 2008, artemisinin-based combination therapy (ACT) 
(artemether–lumefantrine [AL], dihydroartemisinin–
piperaquine [DHA-PP] or artesunate-mefloquine 
[ASMQ]) was introduced as the first-line treatment for 
uncomplicated falciparum malaria and chloroquine has 
been the first-line treatment for vivax malaria [2]. The 
2012 Myanmar National Treatment Guidelines specify 
that a single dose of primaquine should be administered 
following confirmed cases of falciparum malaria and 
a 14-day dose for radical cure of vivax malaria. Policies 
have been implemented for the use of primaquine at var-
ying levels of the health system, allowing the Government 
to limit use of primaquine to facilities that are equipped 
to either test and/or monitor for signs of glucose-6 phos-
phate dehydrogenase (G6PD) deficiency. However, as 
G6PD testing currently is seldom available in the field, 
implementation of this recommendation is limited [3].
To date, several strategies have been in place to ensure 
the appropriate diagnosis and treatment of malaria 
in Myanmar. One of the key interventions in Myan-
mar, through the National Malaria Control Programme 
(NMCP) as well as several non-governmental organiza-
tions (NGOs), has been the training and deployment of 
community health workers (CHWs) who complement 
the care provided by public healthcare workers in rural 
locations, which bear the greatest burden of disease 
[1, 2]. Since 2008, the primary role of these CHWs has 
been to provide access to confirmatory testing and first-
line treatment for patients who present with symptoms 
of vivax or falciparum malaria. CHWs are part of public 
sector health services, but the providers themselves are 
volunteers who depend on the support of a NGO or the 
NMCP [4].
In the private sector, where up to 70% of Myanmar’s 
population receive treatment [5, 6], several initiatives 
have also been in place over recent years to strengthen 
malaria case management. In 2010, the Government of 
Myanmar developed a set of comprehensive interven-
tions outlined in the “Myanmar Artemisinin Resistance 
Containment (MARC)” framework [7]. This included 
several activities to strengthen malaria case manage-
ment services, including the aforementioned scale-up 
of community health workers. As part of the MARC 
framework, in 2012, Population Services International 
(PSI), a US-based NGO, began implementation of the 
artemisinin monotherapy replacement (AMTR) project. 
The aim of the AMTR project was to distribute highly 
subsidized, first-line ACT into the private sector and 
phase out oral artemisinin monotherapy (AMT). Prior 
to the intervention, it was estimated that up to 2.4 mil-
lion packages of oral AMT were being distributed annu-
ally in Myanmar [8]. The AMTR project aimed to remove 
oral AMT from the market through price competition, 
intensive provider behaviour change communication and 
other demand-creation activities [5]. This was comple-
mented with a ban in 2012 by the Government of Myan-
mar on oral AMT in an attempt to curb the widespread 
availability and use of this medicine [2]. While subsidized 
distribution of ACT occurred throughout the country, 
intensive provider behaviour change activities were lim-
ited to the eastern region of the country. These concerted 
efforts resulted in an increase in availability and distribu-
tion of ACT and a reduction in oral AMT in the eastern 
regions of Myanmar since 2012, though oral AMT still 
has a presence on the market [6]. Furthermore, in 2015, 
the AMTR project focused on increasing and scaling-
up access to malaria confirmatory testing across certain 
parts of the country and 60,000 free rapid diagnostic tests 
(RDTs) were distributed in the private sector.
Despite several public and private-sector initiatives to 
better manage patients through appropriate treatment 
and malaria testing, the spread of artemisinin resistance 
in Myanmar is now apparent. While artemisinin resist-
ance was thought to only exist on the Thailand–Myan-
mar border, with many of the aforementioned strategies 
over the past half-decade having focused heavily on this 
area, resistance has now been detected in areas close to 
the border with India [9]. This is of grave concern given 
Myanmar is noted as the anti-malarial resistance gateway 
to the Indian sub-continent and beyond, and thus is criti-
cal to global malaria control and elimination. Detection 
of artemisinin resistance, and the country’s commitment 
to eliminate malaria by 2030, has prompted an emer-
gency re-assessment of malaria control and elimination 
strategies [4].
Key strategies to address malaria control and elimi-
nation efforts in Myanmar are outlined in the National 
Strategic Plan for Intensifying Malaria Control and 
Accelerating Progress towards Malaria Elimination 
(2016–2020) [1]. In the public sector, this includes 
scale-up of the CHW programme to improve cover-
age and access to appropriate malaria testing and treat-
ment. The private sector will be increasingly regulated 
and licensed, with only ‘selected’ private-sector provid-
ers allowed to test and treat patients. Selected outlets 
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include pharmacies, private companies and outlets, 
who will be trained, supervised, and provided with 
malaria commodities, and required to report on case-
load data. In addition, the National Strategic Plan speci-
fies that non-licensed drug vendors, except in special 
circumstances, will be prohibited from treating malaria 
and selling anti-malarial medicines. Several strategies 
will be undertaken to regulate non-licensed drug ven-
dors, including enforcement through judiciary officers. 
Myanmar will also tighten the ban on oral AMT and 
implement police enforcement to stop the sale and dis-
tribution of oral AMT.
Timely and relevant anti-malarial market evidence 
will be useful to help provide a benchmark for Myan-
mar’s National Strategic Plan, to help accelerate progress 
towards elimination goals in the country and to prior-
itize strategic areas. Previous studies on the anti-malarial 
market and malaria diagnostics have been limited to the 
eastern part of the country [6] and, therefore, the perfor-
mance CHWs and private-sector healthcare providers 
for malaria case management services across the coun-
try is largely unknown. Furthermore, the performance of 
the private sector across different geographical regions 
is likely to vary given the lack of uniform strategies to 
improve malaria case management, with most activities 
happening in the eastern part of the country.
The objective of this paper is to provide evidence to 
inform malaria elimination strategy and policy in Myan-
mar. The paper describes the market for malaria medi-
cines and diagnostics among CHW and across the private 
sector. The potential of CHWs and the private sector in 
malaria control and elimination efforts is discussed.
Methods
This study was a cross-sectional survey, which employed 
stratified cluster-random sampling across four regions 
(strata) in Myanmar. The study population consisted of a 
census of all anti-malarial stocking outlets in the selected 
clusters. The data collection lasted over five months, 
from late August 2015 to early January 2016.
ACTwatch project developed the methodology for 
this study [10, 11], and the same methodology was 
employed for three other studies conducted in the GMS 
in 2015/2016 [12]. The ACTwatch project is a multi-
country research project, whose goal is to provide high-
quality evidence on anti-malarial markets all over the 
world. Since its inception, the project has developed, 
applied and documented several standardized tools and 
approaches.
Study population
The study used explicit stratification to provide estimates 
within four study regions: (1) Eastern areas were located 
primarily along the eastern border with Thailand and 
Yunan Province in China, which were part of the AMTR 
intervention programme activities and were expected to 
have different outcomes compared to other regions; (2) 
Central included areas of central Myanmar that were 
adjacent to the AMTR project area in eastern Myan-
mar but were not part of it, and were expected to have 
similar background characteristics to the Eastern region 
(in previous outlet survey studies, this region was typi-
cally considered a comparison region [6]); (3) Western 
included areas within Chin State, Sagaing, and Magway 
Regions which formed immediate or proximate borders 
with India; and, (4) Coastal, within Rakhine State, Mag-
way, Bago and Ayeyarwaddy Regions which formed the 
border with Bangladesh and were part of the coastal area 
(Fig. 1).
Eligibility criteria
All outlets with the potential to sell or distribute anti-
malarial medicines were screened for eligibility. These 
included CHWs, private for-profit facilities, pharmacies, 
general retailers, and itinerant drug vendors (Table 1). All 
outlets, except government health facilities, were eligible 
for interview and an anti-malarial or RDT audit if they 
met at least one of three study criteria: (1) had one or 
more anti-malarial medicines in stock on the day of the 
survey; (2) had one or more anti-malarials reportedly in 
stock within the three months preceding the survey; and/
or, (3) provided malaria blood testing, either microscopy 
or RDT. Public health facilities were excluded from the 
study because permission was not received to audit these 
facilities.
In this study, private-for-profit health facilities, phar-
macies, general retailers, and itinerant drug vendors 
comprise the ‘private sector’. CHWs are described sepa-
rately as a different, public not-for profit channel given 
their mode of operation was different.
Sample size
The study was designed to generate estimates for key 
market indicators within each region. Minimum sample 
size requirements were calculated to estimate, with ±10% 
precision, the following indicators: (1) the proportion of 
private-sector outlets with ACT availability, among out-
lets with anti-malarial(s) in stock on the day of the sur-
vey; and, (2) the proportion of private-sector outlets with 
oral AMT in stock, among outlets with anti-malarial(s) 
in stock on the day of the survey. The minimum number 
of outlets that needed to be screened was determined 
from the required number of anti-malarial stocking 
outlets, and the proportion of screened outlets that had 
anti-malarial(s) from previous studies [13]. That num-
ber was then divided by an estimated average number of 
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private-sector outlets per cluster to attain the minimal 
number of clusters required for the study. In total, 836 
clusters were selected across the four regions.
Sampling approach
Clusters were selected using probability proportionate 
to size (PPS). A cluster was defined as a ‘ward’ in urban 
areas (towns and cities), and as a ‘village tract’ (a cluster 
of several villages) in rural areas. On average, 3000–5000 
people resided in each cluster, but there were geographi-
cal differences.
The sampling frames were constructed using popu-
lation sizes of clusters because the estimated number 
of outlets for each cluster did not exist. The population 
figures were used as a proxy measure with the assump-
tion that the number of outlets within a given cluster 
were correlated with its population size. To manage the 
size of the survey and maintain quality, the survey was 
implemented in two phases, with the Eastern and Cen-
tral regions in phase 1, and Western and Coastal regions 
in phase 2. Each phase had a slightly different sampling 
approach due to limited availability of population data for 
the sampling frame.
Phase 1 data collection used two-stage sampling, where 
larger clusters (townships) formed the first-stage sam-
pling frame. From that, 28 townships were randomly 
selected using PPS. In the second stage, all wards and vil-
lage tracts within the selected townships were listed, and 
systematic random sampling was used to select a fixed 
number of clusters from each township, resulting in the 
final sample of 448 clusters.
Phase 2 data collection used one-stage sampling as the 
actual population numbers of wards and village tracts 
had become available at that time from the 2014 Popu-
lation and Housing Census. Consequently, the sampling 
frame consisted of all clusters (wards and village tracts) 
from each region, and a total of 360 clusters were ran-
domly selected using PPS.
Data collection
Two separate interviewer-training sessions were given, 
which spanned a total of eight days. The training focused 
on identification of outlets and anti-malarial medicines, 
informed consent procedures, and step-by-step walk-
through of a full questionnaire.
Within each selected cluster, a census of all outlets with 
the potential to sell or distribute anti-malarials and/or 
provide malaria blood testing was conducted. The cen-
sus involved systematically looking for outlets in each 
cluster, and using screening questions to identify outlets 
for inclusion in the study. Provider interviews and anti-
malarial audits were conducted in all eligible outlets, 
after informed consent procedures.
For each eligible outlet, interviewers conducted an 
exhaustive audit of all anti-malarials and RDTs in stock 
at the time of the survey. For each and every anti-malarial 
medicine, the audit included formulation, brand name, 
active ingredients and strengths, manufacturer, and 
country of manufacture. The audit also collected infor-
mation on unit costs of anti-malarials, and amount dis-
tributed to individual patients within the previous seven 
days. Basic outlet and provider characteristics, including 
availability of malaria microscopy, were collected. Ques-
tions related to private sector support and engagement 
Central
Eastern
Coastal
Western
Fig. 1 Map of selected clusters
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were also administered to providers. Paper-based ques-
tionnaires and field monitoring sheets were used to 
record information.
Data entry, processing and analysis
Double data entry and verification was performed using 
customised CSPro data entry forms. All data cleaning 
and analysis were completed using Stata 13.1 (©Stata-
Corp, College Station, TX, USA). 2014 UNFPA census 
data was used to calculate sampling weights, applied at 
the township level to account for variations in probabil-
ity of selection. Stata survey settings were used to reflect 
the study design and sampling approach, to compute 
estimates, including those at region-level. Standard error 
estimation, including application of a finite population 
correction, accounted for clustering at the ward/village 
track level. Weighting and finite population correction 
yielded confidence intervals (CI) used for comparison of 
proportions.
Standard indicators were constructed according to 
ACTwatch definitions [10, 11, 14]. All audited anti-malar-
ial medicines were verified and classified using informa-
tion on drug formulation, contents and strengths with 
supporting information, including brand or generic name 
and manufacturer. Anti-malarials were classified as ACT, 
non-artemisinin therapy, and oral or non-oral AMT. A 
generic classification of ACT was used as national policy 
for uncomplicated falciparum malaria was AL, PHA-PPQ 
or ASMQ. Availability of any anti-malarial was defined in 
this study as the proportion of outlets stocking at least 
one anti-malarial among all screened outlets. Other anti-
malarial and RDT availability categories were calculated 
but restricted to those outlets where at least one anti-
malarial was audited. For example, ACT availability (the 
proportion of ACT-stocking outlets) was measured as 
the number of ACT-stocking outlets in the numerator 
and the number of anti-malarial stocking outlets in the 
denominator.
Market share was defined as the relative distribution 
of the anti-malarials sold to individual consumers in the 
week preceding the survey. In order to allow for mean-
ingful market share comparisons between products, 
information about anti-malarial distribution was stand-
ardized to the adult equivalent treatment dose (AETD). 
AETD is the amount of active ingredient necessary to 
treat a 60-kg adult according to World Health Organiza-
tion (WHO) treatment guidelines [14]. Volumes distrib-
uted were calculated by converting provider reports on 
the number of anti-malarials sold in the week prior to the 
survey into AETDs. Volumes were the number of AETDs 
sold or distributed by a provider in the seven days prior 
to the survey. All dosage forms were considered in meas-
uring volumes so as to provide a complete assessment 
of anti-malarial market share. Primaquine distribution 
was not included in calculations of total and relative vol-
umes distributed. This is because primaquine is to be 
used only in combination with either an ACT for falci-
parum malaria, or with chloroquine for all other infec-
tions. Therefore, similar to the treatment of partner drugs 
within an ACT, we only consider volumes distributed for 
primaquine’s partner drugs (ACT or chloroquine).
Provider knowledge was assessed by administering 
knowledge questions to the senior-most provider at all 
anti-malarial-stocking outlets. Providers were asked to 
state the national first-line treatment and dosing regi-
men for uncomplicated falciparum/vivax malaria for a 
60-kg adult. Providers citing any first-line ACT as the 
first-line treatment for falciparum malaria, or chloro-
quine for vivax malaria, were classified as having correct 
knowledge.
Ethical considerations
The study was approved by PSI Research Ethical Board 
registered under the Office of Human Research Protec-
tions (OHRP FWA00009154, IRB#00006961). All inter-
views and product audits were conducted only after 
receiving verbal informed consent from the participating 
providers. Confidentiality and anonymity was maintained 
through all phases of the study, and all standard ethical 
guidelines were followed.
Results
A total of 28,664 outlets that had potential to sell/dis-
tribute anti-malarial medicines were approached to par-
ticipate in the survey across the four regions (Table  2). 
Of these, 28,267 outlets were screened for stocking anti-
malarials or malaria diagnostic testing (309 outlets were 
closed at the time of visit or closed permanently, and 88 
outlet providers refused). Of these, 4416 met the screen-
ing criteria and 4395 were interviewed. The number of 
interviewed outlets was highest in the more populous 
Eastern region (N = 1330), and lowest in Central region 
(N  =  594). Among the interviewed outlets, 3859 were 
found to have at least one anti-malarial in stock at the 
time of the survey, 413 outlets had no anti-malarials in 
stock at the time but reported having stocked an anti-
malarial in the past three months, and 123 had malaria 
diagnostic testing but no anti-malarials. Among outlets 
stocking anti-malarials or malaria tests on the day of sur-
vey, 8735 anti-malarial products and 1635 RDTs were 
audited.
Among all screened outlets, anti-malarial availability 
was as follows: CHW, 45% (N = 2737); private for-profit 
facilities, 50.4%, (N = 610); pharmacies, 46.9% (N = 970); 
general retailers, 4.6% (N =  22,733); and itinerant drug 
vendors, 33.7% (N = 1217).
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Anti‑malarial market composition
Figure 2 shows the relative distribution of all outlets that 
had at least one anti-malarial in stock, by region and 
nationally. Estimates indicate that CHWs comprised 
41.5% of the market composition, while other anti-malar-
ial-stocking outlets were from the private sector (58.5%), 
including general retailers (27.9%), itinerant drug ven-
dors (11.8%), pharmacies (10.9%), and private for-profit 
facilities (7.9%).
Observing regional differences, Eastern and Central 
illustrated a slightly higher market composition of CHWs 
(44.3 and 44.3 %, respectively) compared to Western and 
Coastal (35.0% and 31.6%, respectively). General retail-
ers comprised the majority of the market composition 
in Western (40.5%) and Central (43.7%). Itinerant drug 
vendors comprised between 6.7 and 14.7% of the market 
composition across regions.
Table 2 Total outlet survey sample
Eastern Central Western Coastal Total
Outlets enumerated 8432 7481 5666 7085 28,664
Outlets screened 8271 7393 5598 7005 28,267
Outlets that met screening criteria 1563 710 1149 994 4416
Outlets interviewed 1554 702 1147 992 4395
Outlets that had any anti-malarial at the time of survey 1330 594 1065 870 3859
44.3
8.4
11.2
29.5
6.7
Eastern
N=1,330
44.3
9.9
12.3
18.8
14.7
Central
N=594
35
4.6
7.5
40.5
12.3
Western
N=1,065
31.6
3.2
7.7
43.7
13.7
Coastal
N=870
41.5
7.910.9
27.9
11.8
Naonal
N=3,859
Fig. 2 Anti-malarial market composition
Table 1 Outlet types
Community health workers (CHWs) Village-based volunteers who provide free or highly subsidized health services in remote rural areas. They are 
typically linked with government or non-government not-for-profit organizations, and usually receive train-
ing, support and supplies
Private sector
 Private-for-profit health facilities General practitioners who operate within privately owned facilities that are licensed by Myanmar’s Ministry of 
Health. In some cases, the providers work for Ministry of Health as well and are running these clinics during 
their free time
 Pharmacies Pharmacies and drug stores, usually licensed by the Ministry of Health. They are usually small, privately owned, 
and stock various medicines including prescription-based ones
 General retailers Small grocery stores and village shops that sell fast-moving consumer goods, food and provisions. They often 
stock over-the-counter medicines including anti-malarial drugs but typically are not recognized as drug 
stores, nor hold licenses
 Itinerant drug vendors Informal healthcare providers who are mobile and typically operate in rural areas and cover more than one vil-
lage. Some are retired healthcare providers from various government ministries but are no longer registered. 
They are typically not linked with regulatory authorities
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Availability of anti‑malarial medicines and diagnostics
Availability of anti-malarial medicines and malaria diag-
nostics among outlets stocking at least one anti-malarial 
is shown in Tables 3 and 4. Among anti-malarial-stocking 
CHWs, 83.1% stocked an ACT and 67.0% stocked chloro-
quine. Oral AMT was available in less than 5% of CHWs 
(2.9%). Around three out of four CHWs stocked a malaria 
blood test (RDT or microscopy) (77.7%). There were few 
Table 3 CHW availability of anti-malarial drugs and malaria diagnostics, among anti-malarial-stocking outlets, by region
AMT artemisinin monotherapy
a Anti-malarial-stocking outlets have at least one anti-malarial in stock on the day of the survey, verified by presence of at least one anti-malarial recorded in the ant-
imalarial audit sheet
b At the time of the 2015/2016 Myanmar ACTwatch outlet survey, AL, DHA-PP, and ASMQ were the first-line treatments for uncomplicated falciparum malaria. There 
was no ASMQ audited during the 2015/2016 survey
c Blood testing availability is reported among outlets that either had anti-malarials in stock on the day of the survey or reportedly stocked anti-malarials in the 
previous 3 months
CHW
Total(N = 1263) (95% CI)
Eastern
(N = 545) (95% CI)
Central
(N = 244) (95% CI)
Western
(N = 242) (95% CI)
Coastal
N = (232) (95% CI)
Availability of anti-malarialsa
 Any ACTb 83.1 (80.1, 86.1) 87.8 (83.9, 90.9) 76.2 (69.8, 81.6) 83.3 (76.1, 88.6) 91.7 (86.2, 95.1)
 Chloroquine 67.0 (63.5, 70.5) 67.6 (63.0, 71.8) 65.4 (58.8, 71.4) 76.0 (68.4, 82.3) 67.3 (59.0, 74.6)
 Primaquine 62.6 (58.6, 66.5) 60.3 (55.3, 65.2) 58.1 (50.4, 65.3) 72.7 (64.2, 79.8) 74.7 (67.5, 80.8)
 Oral AMT 2.9 (1.6, 4.2) 2.4 (1.2, 4.7) 4.0 (2.1, 7.5) 4.5 (2.6, 7.9) 0.6 (0.2, 2.2)
 Non-oral AMT 8.9 (6.5, 11.3) 6.5 (4.1, 10.2) 12.3 (8.3, 17.8) 7.9 (5.1, 12.0) 5.0 (2.4, 10.2)
N = 1382 N = 597 N = 277 N = 257 N = 251
Availability of blood testingc
 Any malaria 
blood testing
77.7 (74.4, 81.0) 79.3 (75.5, 82.7) 72.5 (65.6, 78.4) 83.6 (78.1, 87.9) 86.1 (79.7, 90.7)
 Malaria  
microscopy
0.2 (0.0, 0.5) 0.1 (0.0, 0.7) 0.3 (0.0, 2.1) 1.1 (0.2, 5.9) 0.0
 RDTs 77.7 (74.4, 81.0) 79.3 (75.5, 82.7) 72.5 (65.6, 78.4) 83.6 (78.1, 87.9) 86.1 (79.7, 90.7)
Table 4 Private sector availability of anti-malarial drugs and malaria diagnostics, among anti-malarial-stocking outlets
AMT artemisinin monotherapy
a Anti-malarial-stocking outlets have at least one anti-malarial in stock on the day of the survey, verified by presence of at least one anti-malarial recorded in the anti-
malarial audit sheet
b At the time of the 2015/2016 Myanmar ACTwatch outlet survey, AL, DHA-PP, and ASMQ were the first-line treatments for uncomplicated falciparum malaria. There 
was no ASMQ audited during the 2015/2016 survey
c Blood testing availability is reported among outlets that either had anti-malarials in stock on the day of the survey or reportedly stocked anti-malarials in the 
previous 3 months
Private Sector Total 
N = 2596 (95% CI)
Eastern
(N = 785) (95% CI)
Central
(N = 350) (95% CI)
Western
(N = 823) (95% CI)
Coastal
N = (638) (95% CI)
Availability of anti-malarialsa
 Any ACTb 41.7 (36.9, 46.6) 65.6 (59.5, 71.2) 36.7 (27.6, 46.8) 14.1 (11.2, 17.5) 19.0 (14.2, 25.0)
 Chloroquine 41.8 (38.4, 45.3) 24 (20.1, 28.3) 43.5 (37.0, 50.2) 47.7 (41.6, 53.8) 68.6 (62.4, 74.2)
 Primaquine 7.7 (4.9, 10.4) 7.5 (5.4, 10.4) 11.1 (6.4, 18.4) 2.9 (1.6, 5.2) 1.0 (0.5, 1.9)
 Oral AMT 27.7 (23.8, 31.7) 25.0 (18.9, 32.4) 31.4 (24.8, 38.9) 54.1 (49.4, 58.7) 15.4 (11.7, 20.2)
 Non-oral AMT 11 (8.6, 13.4) 11.7 (7.7, 17.3) 11.8 (8.6, 16.2) 18.3 (15.0, 22.2) 5.5 (3.3, 9.0)
N = 2890 N = 904 N = 398 N = 877 N = 711
Availability of blood testingc
 Any malaria blood 
testing
15.4 (12.6, 18.1) 21.0 (17.2, 25.4) 14.8 (10.4, 20.5) 8.4 (6.0, 11.7) 8.7 (5.7, 13.0)
 Malaria microscopy 0.6 (0.2, 0.9) 0.6 (0.3, 1.2) 0.7 (0.2, 2.0) 0.7 (0.3, 1.5) 0.2 (0.0, 0.8)
 RDTs 14.9 (12.3, 17.6) 20.5 (16.7, 24.8) 14.2 (9.9, 19.8) 8.2 (5.8, 11.4) 8.7 (5.7, 13.0)
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regional differences between indicators among CHWs 
(Table 3).
ACT was available in fewer than half of the anti-malar-
ial-stocking private sector outlets (41.7%) (Table 4). ACT 
availability was highest in Eastern (65.6%), followed by 
Central (36.7%), Coastal (19.0%) and Western (14.1%) 
regions. Chloroquine was found in 41.8% of private-
sector outlets. Chloroquine availability was highest in 
Coastal (68.6%), followed by Western (47.7%), Central 
(43.5%) and Eastern (24.0%). Availability of primaquine 
was rare (7.7%). Oral AMT availability was found in 
27.7% of the private sector, and ranged from 54.1% of 
anti-malarial-stocking outlets in the Western region to 
15.4% in the Coastal region. Availability of non-oral AMT 
was less than 20% across the private sector, and high-
est in the Western region (18.3%). Malaria blood testing 
was available in 15.4% of the anti-malarial-stocking pri-
vate sector outlets: RDT (14.9%) rather than microscopy 
(0.6%). Malaria blood testing was highest in the Eastern 
region (20.5%) and lowest in the Western and Coastal 
regions (<10%).
Anti‑malarial market share
Figure 3 illustrates the market share of different catego-
ries of anti-malarial medicines sold or distributed within 
seven days prior to the survey among CHW. 71.6% of 
the market share comprised ACT, followed by chloro-
quine (22.3%). Distribution of oral AMT was rare, 3.7% 
of the market share. ACT market share was lowest in the 
Western region (36.6%) compared to other regions which 
had an ACT market share greater than 60%.
Figure 4 illustrates the market share of different catego-
ries of anti-malarial medicines sold or distributed within 
seven days prior to the survey  in the private sector. The 
national private-sector anti-malarial market share com-
prised ACT (44.0%), chloroquine (26.6%), oral AMT 
(19.6%). ACT market share was highest in the Eastern 
region, accounting for 59.1% of the market share and low-
est in Western region (17.6%). Chloroquine market share 
was lowest in the Eastern region (8.3%) but similar across 
other regions, ranging from 32.6 to 40.5%. Oral AMT was 
distributed across all regions, and highest in the Western 
region (34.5%) and lowest in the Coastal region (13.1%). 
Non-oral AMT market share was less than 10% across 
regions.
The relative private sector market share across out-
let types is also presented, excluding contributions from 
CHW (Additional file 1). In the private sector, the major-
ity of anti-malarials were distributed by pharmacies 
(39.1%). Private-for-profit facilities, general retailers and 
itinerant drug vendors accounted for around 60% of the 
total private sector market share (19.1, 21.8 and 20.3%, 
respectively).
Providers’ knowledge
More than half of CHWs could correctly state the 
national first-line treatment for uncomplicated falcipa-
rum and vivax malaria (59.2 and 56.9%, respectively) 
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Fig. 3 Anti-malarial market share: CHW
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(Table 5). Less than 20% of private-sector providers could 
correctly state the first-line treatment for uncomplicated 
falciparum and vivax malaria (15.8 and 13.2%, respec-
tively) (Table  6). Region-specific differences within the 
private sector were also present, where less than 7% of 
providers in the Western and Coastal regions were able 
to correctly state the first-line treatment. There were few 
regional differences by CHW.
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Fig. 4 Anti-malarial market share: Private Sector
Table 5 CHW knowledge of the first-line treatment guidelines
CHW
Total N = 1382  
(95% CI)
Eastern
(N = 597)  
(95% CI)
Central
(N = 277)  
(95% CI)
Western
(N = 257)  
(95% CI)
Coastal
N = (251)  
(95% CI)
Proportion of providers who:
 Correctly stated national first-line 
treatment for uncomplicated 
falciparum malaria
59.2 (55.1, 63.2) 60.7 (55.5, 65.7) 57.2 (49.8, 64.3) 65.7 (57.9, 72.7) 51.7 (43.1, 60.3)
 Correctly stated national first-line 
treatment for uncomplicated 
vivax malaria
56.9 (52.9, 60.9) 60.5 (55.9, 64.1) 56.9 (49.3, 64.1) 64.9 (57.0, 73.2) 50.4 (42.3, 58.5)
Table 6 Private sector knowledge of the first-line treatment guidelines
Private sector total
N = 2596
(95% CI)
Eastern
(N = 904)
(95% CI)
Central
(N = 398)
(95% CI)
Western
(N = 877)
(95% CI)
Coastal
N = (711)
(95% CI)
Proportion of providers who:
Correctly stated national first-line treatment  
for uncomplicated falciparum malaria
15.8 (12.6, 19.0) 19.8 (16.7–23.3) 18.3 (12.6–26.0) 5.0 (3.3–7.4) 5.5 (3.3–8.9)
Correctly stated national first-line treatment  
for uncomplicated vivax malaria
13.2 (10.5, 15.9) 14.7 (11.6, 18.4) 14.7 (10.1, 20.8) 4.3 (2.7, 6.6) 6.3 (4.2, 9.4)
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Supportive supervision and passive surveillance
The majority of CHW (60.7%) reportedly receiving train-
ing on malaria diagnosis, and 59.6% on national malaria 
treatment guidelines (Table  7). Almost 40% report-
edly received a supervisory or regulatory visit within 
12  months. Similarly, 77.3% reportedly kept records 
on number of patients tested or treated for malaria and 
76.0% said they reported these numbers to government 
(51.8%) or NGOs (26.2%). There were few regional differ-
ences among CHW.
Less than 10% of private-sector outlets reportedly 
received training within the past year, and supervisory/
regulatory visits were reported by only one in four pro-
viders (19.9%) (Table 8). Only 12.2% kept patient records, 
and less than 10% reported to government (2.9%) or 
NGOs (6.6%). Private sector region-specific differ-
ences were observed, with highest numbers in East-
ern region, with almost half of private-sector providers 
(47.8%) reporting supervisory/regulatory visits. However, 
all other indicators were typically less than 15%, with 
less than 6% outlets located in the Western and Cen-
tral region reportedly receiving training on diagnosis, 
national treatment guidelines, receiving a supervisory 
visit, and reporting on caseload data.
Discussion
The 2015/2016 outlet survey presents, for the first time, 
national estimates of the anti-malarial market among 
CHWs and the private sector in Myanmar. Findings point 
to a strong foundation for malaria case management 
among CHWs but highlight key gaps in the private sector 
as well as notable regional differences. The results also 
point to the urgent need to remove oral AMT from the 
private sector marketplace.
CHW readiness for appropriate malaria case management
Findings from the outlet survey illustrate the importance 
of CHWs, with up to 40% of the anti-malarial service 
delivery points comprising of these providers, though this 
contribution is likely to be lower if public health facilities 
were included in the sample. These providers were more 
prevalent in Eastern areas of the country, which reflect 
several MARC initiatives to scale-up these community-
based providers.
Table 7 CHW supervision, support and caseload reporting
CHW total %  
(95% CI)
Eastern %  
(95% CI)
Central %  
(95% CI)
Western %  
(95% CI)
Coastal %  
(95% CI)
N = 1461 N = 625 N = 301 N = 264 N = 271
Proportion of providers who:
 Trained on malaria diagnosis (RDT 
and/or microscopy)
60.7 (57.0, 64.4) 63.4 (58.7, 67.9) 56.5 (49.5, 63.2) 66.4 (58.0, 73.8) 64.5 (56.3, 71.8)
N = 1461 N = 624 N = 301 N = 264 N = 272
Trained on national malaria treat-
ment guidelines
59.6 (55.8, 63.4) 62.3 (57.3, 67.1) 57.3 (50.3, 64.1) 60.5 (51.4, 68.8) 60.1 (52.5, 67.3)
N = 1458 N = 626 N = 300 N = 263 N = 269
Reported receiving a supervisory 
or regulatory visit within the past 
year
39.1 (35.8, 42.4) 59.5 (53.6, 65.0) 28.3 (23.4, 33.8) 38.6 (31.2, 46.5) 28.8 (22.4, 36.3)
N = 1461 N = 625 N = 301 N = 264 N = 271
Kept records on number of patients 
tested/treated for malaria
77.3 (74.1, 80.6) 76.5 (71.9, 80.7) 74.8 (68.4, 80.2) 82.4 (76.5, 87.1) 83.7 (75.9, 89.3)
N = 1459 N = 623 N = 301 N = 264 N = 271
Reported numbers of patients 
tested/treated for malaria to 
government or NGO
76.0 (72.6, 79.3) 75.6 (70.9, 79.7) 73.5 (67.0, 79.1) 81.4 (75.3, 86.2) 81.2 (72.9, 87.4)
N = 1459 N = 623 N = 301 N = 264 N = 271
Reported numbers to government 51.8 (48.1, 55.5) 40.3 (35.5, 45.2) 57.7 (51.3, 63.9) 38.1 (30.9, 45.9) 62.5 (52.8, 71.2)
N = 1459 N = 623 N = 301 N = 264 N = 271
Reported numbers of to a NGO 26.2 (22.6, 29.9) 36.4 (31.3, 41.8) 19.2 (13.9, 26.0) 43.2 (35.2, 51.7) 20.0 (12.6, 30.2)
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Readiness for malaria case management implies hav-
ing malaria commodities (first-line treatment for uncom-
plicated malaria and/or confirmatory testing) in stock at 
the time of survey. The findings point to strong readiness 
for appropriate malaria case management among CHWs 
who were found to be stocking anti-malarials. More than 
three-quarters had confirmatory testing available. Over 
80% had first-line treatment for falciparum malaria in 
stock and more than half had the first-line treatment for 
vivax malaria. More than half of the CHW received train-
ing on national treatment guidelines and/or testing, and 
over three-quarters kept malaria case load data.
These findings suggest that there is merit in expanding 
and scaling-up CHWs further as a means to reach remote 
communities with malaria commodities, including expan-
sion to the Western region where malaria endemicity is 
even higher than in other parts of the country. This rec-
ommendation is supported by several studies in Myanmar 
which have shown the CHW programme to be relatively 
inexpensive to implement [15], to have improved access to 
early and reliable diagnosis and treatment among margin-
alized groups [16] and to have improved malaria health-
care [17]. Key challenges to be addressed include ensuring 
a constant supply of first-line treatments, given over half 
of the CHWs were not stocking any anti-malarials on the 
day of survey or in the past 3 months. It is not clear from 
this study if this finding reflects long term stock-outs or 
rather inactive CHW. While over 40,000 CHW have been 
deployed over the years by the government and other 
partners in Myanmar, it is noteworthy that not all of these 
community based providers may be tasked with the pro-
vision of malaria commodities. Moreover, there is a high 
rate of attrition of CHWs and it was reported in 2015 that 
only 15,000 were currently active or functional as per the 
National Strategic Plan [1]. Several strategies may need 
to be considered to improve retention and motivation of 
CHWs, such as incentive schemes, training and supervi-
sion, and ensuring regular supply of commodities [18–21].
Table 8 Private sector supervision, support and caseload reporting
Private sector total %  
(95% CI)
Eastern %  
(95% CI)
Central %  
(95% CI)
Western %  
(95% CI)
Coastal %  
(95% CI)
N = 2925 N = 923 N = 400 N = 882 N = 720
Proportion of providers who:
 Trained on malaria diagnosis 
(RDT and/or microscopy)
8.0 (5.9, 10.2) 12.0 (9.1, 15.7) 8.1 (4.8, 13.2) 4.8 (3.2, 7.1) 1.7 (0.9, 3.0)
N = 2924 N = 922 N = 400 N = 882 N = 720
Trained on national malaria 
treatment guidelines
9.4 (6.9, 11.8) 12.9 (9.7, 16.8) 9.0 (5.3, 14.8) 5.2 (3.7, 7.4) 5.3 (2.8, 9.7)
N = 2917 N = 921 N = 399 N = 879 N = 718
Reported receiving a super-
visory or regulatory visit 
within the past year
19.9 (17.1, 22.7) 47.8 (41.2, 54.4) 8.7 (5.6, 13.4) 2.7 (1.4, 5.2) 2.0 (1.1, 3.8)
N = 2920 N = 924 N = 397 N = 881 N = 718
Kept records on number of 
patients tested/treated for 
malaria
12.2 (9.3, 15.2) 16.3 (13.1, 20.1) 13.3 (8.5, 20.3) 6.4 (4.2, 9.6) 3.9 (1.8, 8.4)
N = 2905 N = 921 N = 386 N = 880 N = 718
Reported numbers of 
patients tested/treated for 
malaria to government or 
NGO
9.4 (6.7, 12.1) 13.2 (10.5, 16.6) 9.7 (5.4, 16.6) 4.5 (2.6, 7.5) 3.1 (1.2, 7.8)
N = 2905 N = 921 N = 396 N = 880 N = 718
Reported numbers to gov-
ernment
2.9 (1.7, 4.2) 2.7 (1.7, 4.3) 3.5 (1.8, 6.6) 2.4 (1.3, 4.6) 2.3 (0.6, 7.7)
N = 2905 N = 921 N = 396 N = 880 N = 718
Reported numbers of to a 
NGO
6.6 (4.6, 8.6) 10.4 (7.9, 13.6) 6.6 (3.6, 11.8) 2.0 (0.8, 4.8) 0.8 (0.4, 1.8)
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National guidelines stipulate that CHWs are authorized 
and recommended to provide a low dose of primaquine 
(0.25 mg) once weekly for eight weeks after chloroquine 
to prevent vivax malaria relapse, which has been found 
to be the front-line therapy for radical cure of P. vivax 
[22]. A single dose of primaquine following ACT for fal-
ciparum malaria is also recommended in the national 
treatment guidelines in order to substantially reduce 
transmission potential [23]. The outlet survey found that 
availability of primaquine among CHW however was 
moderate, around 60%. This may highlight challenges 
with procurement of the medicine to maintain constant 
supply, although availability of primaquine was much 
higher in Myanmar than in some neighbouring ACT-
watch countries [24, 25]. This gap in CHW readiness 
to provide primaquine will be of importance to address 
given evidence that the addition of a single dose of pri-
maquine could have a major effect on malaria transmis-
sion from falciparum malaria patients [26].
Role of the private sector in appropriate malaria case 
management
Consistent with findings from other countries in the 
GMS, the private sector plays an important role in 
malaria case management [24, 25]. Results from this 
study show that the private-sector comprised over half 
of the anti-malarial service delivery points, and this was 
most notable in the Western and Coastal regions. Myan-
mar’s private sector was typically made up of pharmacies, 
general retailers and itinerant drug vendors, all of which 
were allowed to test and treat for malaria according to 
national policy at the time of the survey. Private sector 
market share data revealed that pharmacies distributed 
most of the private sector anti-malarials, however gen-
eral retailers and itinerant drug vendors were also com-
mon sources, illustrating the need to reach these types of 
outlets as part of elimination strategies.
These findings have several implications for Myan-
mar’s malaria National Strategic Plan as it sets out to 
increase regulation of several private sector outlet types, 
and clamp down on outlets that are not licensed. Remov-
ing general retailers and itinerant drug vendors from the 
anti-malarial market, or making it illegal for them to sell 
anti-malarials or provide testing may result in a lack of 
access to malaria commodities. Several success stories 
have been demonstrated by the AMTR project which 
has specifically included these types of outlets as part of 
their strategy to promote ACT uptake through behaviour 
change communication and product promoter visits [5, 
6]. While it may not be feasible to scale-up or replicate 
such an initiative to the entire country, ensuring that 
these anti-malarial-stocking providers have constant sup-
ply and access to malaria commodities may be an initial 
step to maintain existing levels of coverage and access 
to malaria treatment. Private sector training, capac-
ity-building and demand generation will be important 
strategies to complement efforts to increase coverage of 
malaria commodities in the private sector [27].
Readiness and performance of the private sector
The private sector was generally less well equipped to test 
and appropriately treat malaria infections compared with 
CHWs. Where anti-malarials were available in the pri-
vate sector, fewer than half of anti-malarial-stocking out-
lets had first-line treatments available for falciparum or 
vivax malaria. There were, however, notable differences 
in availability of first-line treatments according to dif-
ferent geographical areas. Availability and market share 
of first-line treatment for falciparum malaria, ACT, was 
more common in the Eastern region than in the West-
ern or Coastal regions. Over 60% of the anti-malarials 
distributed in Eastern Myanmar were ACT compared to 
18% in the Western region. These findings are most likely 
attributable to several initiatives, including the AMTR 
project, which has included intensified activities across 
the Eastern part of Myanmar to increase demand and 
uptake of ACT, as previously mentioned.
Availability of malaria blood testing in the private sec-
tor was generally low, with 15% or less of outlets having 
RDT or microscopy available. These gaps in private sec-
tor readiness are a threat to appropriate management of 
suspected cases, given the real likelihood of presumptive 
anti-malarial treatment. In particular, while the market 
share data suggest that over 70% of anti-malarials dis-
tributed in the week prior to the survey were first-line 
treatments for falciparum or vivax malaria in the private 
sector, it is highly likely that most of these were given 
presumptively as providers did not have access to malaria 
tests. Without diagnostic blood tests, providers had no 
reliable way of differentiating the types of malaria infec-
tions. As the national malaria treatment guidelines are 
different for falciparum and vivax malaria, adhering to 
national treatment guidelines was inherently impossible 
for most private sector providers in the absence of con-
firmatory testing.
As the malaria National Strategic Plan stipulates uni-
versal coverage of malaria testing, several strategies are 
needed to scale-up coverage of diagnostics, including 
efforts that are already underway as part of the AMTR 
project to promote access of RDTs in the private sec-
tor. Strategies may include the provision of training and 
supervision to administer parasitological testing, as well 
as incentive models for providers, and maintaining con-
stant supply of RDTs [28]. From the demand side this will 
require promoting RDTs as an important commodity for 
which patients are willing to pay for [29]. In fact, evidence 
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suggests that the introduction of RDTs in Myanmar may 
be highly acceptable, even among the informal private 
sector, and could serve to promote provider empower-
ment and improve patient-provider relationships [30]. 
Other research has shown successful outcomes after 
introducing RDTs in the private sector [31, 32]. However, 
challenges with adhering to different treatment regimens 
for falciparum and vivax malaria based on RDT results, 
as well as a focus on what to do for a negative RDT result, 
are indicative of the need to promote training and super-
vision in light of any large-scale roll-out of RDTs in the 
private sector [33]. Lessons learnt from Cambodia’s expe-
rience of introducing RDTs in the private sector may be 
useful to review in light of any national scale-up of RDTs 
across Myanmar [28].
Private sector availability and distribution of oral 
artemisinin monotherapy
Oral AMT poses a serious threat to the continued effi-
cacy of artemisinins in Myanmar and across the GMS. 
Since 2008, the WHO has called for a ban on this mono-
therapy, and in 2012 Myanmar followed suit with other 
countries in the GMS, issuing a ban on the importation of 
oral AMT. However, data point to the widespread avail-
ability and distribution of this anti-malarial in the private 
sector, accounting for one in every four anti-malarials 
distributed. Results were most concerning across the 
Western region of the country, where one in three out-
lets were found to have oral AMT in stock, accounting 
for 34.5% of the market share. Oral AMT was also most 
commonly distributed among itinerant drug vendors, 
although other outlet types play an important role.
While several initiatives have been in place in Eastern 
Myanmar to remove this from the market, results point 
to the fact that oral AMT persists, with 25% of outlets 
stocking this in 2015/2016, an overall 17-point percent-
age increase from the previous sub-national survey 
implemented in project intervention areas of Eastern 
Myanmar [6]. The reasons for this increase are unclear. It 
is postulated that increases may be due to profit margins 
obtained from oral AMT versus highly subsided ACT, or 
a push by providers and manufactures to sell soon to be 
expired stock, or/and consumer demand for this medi-
cine [34]. This may also reflect low levels of provider 
awareness about recommended first-line treatments 
and/or beliefs and preferences for non-first-line medi-
cines [35–37]. Further research is being implemented to 
understand provider perceptions around oral AMT as a 
means to explain stocking and dispensing practices.
Perhaps of gravest concern is the possibility that actual 
market share of oral AMT was higher than estimated by 
the survey. The ACTwatch outlet survey analysis assumes 
a full course AETD to calculate the basic unit for market 
share. However, in reality the actual sale to patients may 
be less than a full course treatment. In Myanmar where 
ACT was commonly sold as full course treatments, the 
situation is rather different with oral AMT, which was 
typically dispensed as one or two tablets to a patient 
instead of the full AETD of 19.2 tablets with which oral 
AMT market share is calculated. Therefore, the propor-
tion of patients that are treated with oral AMT relative 
to other types of anti-malarials is likely much higher than 
the market share estimated using AETDs distributed.
The results from this survey point to the fact that oral 
AMT remains a serious public health concern in Myan-
mar. Several reasons for the persistent availability and 
sale of this medicine have been postulated, including a 
relatively lenient ban which allows distributors to con-
tinue to import and sell this drug [6]. Action is urgently 
required to address this finding of grave public health 
significance.
Provider knowledge
Provider knowledge was generally lower in the private 
sector compared to CHWs, with slightly fewer than half 
of these providers knowing the first-line treatment for 
either falciparum or vivax malaria. Other studies have 
shown that provider knowledge of medicines and doses, 
particularly in the private sector, is often poor [38, 39]. 
Indeed, in the private sector, knowledge was less than 
20% and exceptionally low in the Western region, where 
less than 5% of providers could correctly state the first-
line treatment for falciparum or vivax malaria. This 
speaks to the need to promote provider awareness of 
the first-line treatment regimens for falciparum or vivax 
malaria.
Increasing provider knowledge may be a first step 
towards ensuring the delivery of first-line treatments. 
That said, some studies have found no evidence of a 
relationship between providers’ knowledge and prac-
tice, and have suggested that provider preference is a 
stronger predictor of appropriate case management 
practices [40]. As such, simply increasing knowledge 
of the first-line treatment may have a limited effect, as 
supported by other studies [41–43]. This points to the 
importance of designing interventions that strive to 
change what providers think and believe to be appropri-
ate, not only to enhance what they know. This could be 
complemented with widespread behaviour change com-
munication, alerting communities to the first-line treat-
ments, to the importance of receiving a confirmatory 
test prior to treatment, and dangers of oral AMT and 
sub-clinical dosing. Such multi-pronged strategies will 
be important in Myanmar to accelerate universal cov-
erage of confirmatory testing and appropriate malaria 
treatment.
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Supervision and malaria caseload reporting
Overall private sector supervision, training on either 
national guidelines or diagnostic testing was low with fewer 
than one in five providers reporting these activities. The 
exception to this was in the Eastern region, where over half 
of the providers received a supervisory visit. This is most 
likely attributable to the AMTR supporting interventions, 
which includes routine visits from product promoters to 
pharmacies, general retailers and itinerant drug vendors.
These important benchmarks will be useful to guide 
future national strategy, which has proposed that the 
anti-malarial-stocking private sector should report on 
caseload data. Motivating these private-sector outlets 
will be key to ensure they report on testing and treat-
ment outcomes. However, there are notable challenges 
with private sector caseload reporting, including a lack of 
provider incentives and operation of this sector outside 
the National Health Management Information Services 
(HMIS) [44]. Of promise is that several private sec-
tor initiatives are in place to do this, including the GMS 
Elimination of Malaria through Surveillance Programme 
(GEMS) which aims to actively increase malaria testing, 
treatment and reporting in the private sector through 
training, supervision and surveillance [45]. Caseload data 
from the private sector will be integrated with public sec-
tor data to provide national programmes with a more 
complete picture of malaria burden to respond to all 
detected cases.
Study limitations
Some limitations are acknowledged. First, as the study 
excluded public health facilities due to operational con-
straints, the total anti-malarial market for the whole 
country could not be estimated. A follow-up survey that 
includes public health facilities would be useful to explore 
the readiness of the public sector and allow for the total 
anti-malarial market share to be calculated. Second, as the 
survey was cross-sectional it could not track the actual 
movement of drug stocks at the outlets. For this reason, 
all market share calculations were based on reported sales 
within one week and were subject to recall bias and volatil-
ity of the market. Lastly, the data collection period spanned 
more than four months from the end of August 2015 to 
early January 2016, and anti-malarial markets might have 
shifted during that time due to seasonal variations.
Regardless of the aforesaid limitations, the study was 
the first to produce national estimates of the anti-malarial 
market among CHWs and the private sector in Myanmar. 
As Myanmar has the highest burden of malaria cases in 
GMS and moves towards malaria elimination, the need 
for a comprehensive picture of entire malaria testing and 
treatment landscape was never more pressing.
Conclusions
Results from this study suggest there are key gaps in 
private-sector readiness for appropriate malaria case 
management, and to some extent these gaps are also 
observed among CHWs. Availability of first-line treat-
ments and malaria diagnostic tests was moderately high 
among the CHWs. These providers may be an impor-
tant channel to reach remote rural communities, but it 
will be necessary to maintain constant supply of com-
modities to ensure universal coverage of confirmatory 
testing and national first-line treatment. The private 
sector remains responsible for most of malaria test-
ing and treatment in Myanmar, and while most of the 
anti-malarials distributed were first-line treatments, 
availability of confirmatory testing was rare, meaning 
that most patients are being treated presumptively with 
either chloroquine or ACT. Of great urgency is the need 
to remove the widespread availability and distribution 
of oral AMT, which threatens global progress towards 
malaria control and case management. Poor private-
sector knowledge, combined with lack of training or 
supervision, further compounds the situation. While 
several strategies have focused on strengthening the pri-
vate sector in the eastern part of the country, and results 
from the private sector in this area are more promising, 
these strategies must be intensified and scaled up, using 
a multipronged approach to promote both provider and 
consumer behaviour change. Future policies and inter-
ventions on malaria control and elimination in Myan-
mar should take these factors into consideration across 
all phases of implementation.
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